Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 1338-1341

  Forthal, Donald N ^a,d   Landucci, Gary ^a   Haubrich, Richard ^b   Keenan, Bobi ^a   Kuppermann, Baruch D ^a   Tilles, Jeremiah G ^a   Kaplan, Jonathan ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RETINITIS; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS RETINITIS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; SURVIVAL RATE; TIME FACTORS;

EID: 0033375327     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314988     Document Type: Article

References (13)

1. Mills GD, Jones PD, Relationship between CD4 lymphocyte count and AIDS morality, 1986-1991. AIDS 1993;7:1383-6.
2. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX, The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51-63.
3. Ahmad A, Menezes J. Positive correlation between the natural killer and gp 120/41-specific antibody-dependent cellular cytotoxic effector functions in HIV-infected individuals. J Aquir Immune Defic Syndr Hum Retrovirol 1995;10:115-9.
4. Rook AH, Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988;10:S460-7.
5. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
6. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4' cell count. JAMA 1998;279:35-40.
7. Ruiz L, Romeu J, Clolet B, et al, Quantitative HIV-1 RNA its a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300 × 10(6)/1. AIDS 1996;10:F39-44.
8. Nightingale SD, Jockusch JD, Hasland I, Cal SX, Peterson DM, Loss SD. Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection. Arch Intern Med 1993;153:1313-8.
9. Tyler DS, Stanley SD, Nastala CA, et al, Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990;144:3375-84.
10. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996;157:2168-73.
11. Walsh JC, Jones CD, Barnes EA, Gazzard BG, Mitchell SM. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 1998;12:613-8.
12. Cameron DW, Heath-Chiozzi M, Danner S. et al, Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998;351:543-9.
13. Haubrich R, Lalezari J, Follansbee SE, et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998;3:33-42.